Cathepsin B Acts as a Dominant Execution Protease in Tumor Cell Apoptosis Induced by Tumor Necrosis Factor by Foghsgaard, Lasse et al.
 

 
 The Rockefeller University Press, 0021-9525/2001/05/999/11 $5.00
The Journal of Cell Biology, Volume 153, Number 5, May 28, 2001 999–1009
http://www.jcb.org/cgi/content/full/153/5/999 999
 
Cathepsin B Acts as a Dominant Execution Protease in Tumor 
 
Cell Apoptosis Induced by Tumor Necrosis Factor
 
✪
 
Lasse Foghsgaard,* Dorte Wissing,* Daniel Mauch,
 
‡ 
 
Ulrik Lademann,* Lone Bastholm,
 
§ 
 
Marianne Boes,
 
  
 
Folmer Elling,
 
§ 
 
Marcel Leist,
 
‡¶
 
 and Marja Jäättelä*
 
*Apoptosis Laboratory, Danish Cancer Society, Copenhagen, Denmark; 
 
‡
 
Department of Molecular Toxicology, University of 
Konstanz, Konstanz, Germany; 
 
§
 
Institute of Molecular Pathology, University of Copenhagen, Copenhagen, Denmark; 
 
 
 
Department of Pathology, Harvard Medical School, Boston, Massachusetts; and 
 
¶
 
H. Lundbeck A/S, Valby, Denmark
 
Abstract. 
 
Death receptors can trigger cell demise de-
pendent or independent of caspases. In WEHI-S ﬁbro-
sarcoma cells, tumor necrosis factor (TNF) induced an
increase in cytosolic cathepsin B activity followed by
death with apoptotic features. Surprisingly, this process
was enhanced by low, but effectively inhibiting, concen-
trations of pan-caspase inhibitors. Contrary to caspase
inhibitors, a panel of pharmacological cathepsin B inhib-
itors, the endogenous cathepsin inhibitor cystatin A as
well as antisense-mediated depletion of cathepsin B res-
cued WEHI-S cells from apoptosis triggered by TNF or
TNF-related apoptosis-inducing ligand. Thus, cathepsin
B can take over the role of the dominant execution pro-
tease in death receptor-induced apoptosis. The conser-
vation of this alternative execution pathway was further
examined in other tumor cell lines. Here, cathepsin B
acted as an essential downstream mediator of TNF-trig-
gered and caspase-initiated apoptosis cascade, whereas
apoptosis of primary cells was only minimally depen-
dent on cathepsin B. These data imply that cathepsin B,
which is commonly overexpressed in human primary tu-
mors, may have two opposing roles in malignancy, re-
ducing it by its proapoptotic features and enhancing it
by its known facilitation of invasion.
Key words: apoptosis • cancer • caspase independent
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Introduction
 
Tumor necrosis factor (TNF)
 
1
 
 is a multifunctional cytokine
capable of inducing several biological responses like apop-
tosis, inflammation, and stress response (Ashkenazi and
Dixit, 1999; Wallach et al., 1999). The numerous biological
effects of TNF are signaled via two distinct cell surface re-
ceptors, TNF receptor (TNF-R) 1 and TNF-R2, the former
being the major signaling receptor in most cells. The intracel-
lular part of the TNF-R1 contains a sequence called a death
domain, which is highly conserved among various death-
inducing receptors of TNF-R superfamily and is required for
the induction of apoptosis by them. Binding of TNF to TNF-
R1 leads to the trimerization of the death domains and their
subsequent binding to cytosolic death domain–containing
proteins, TNF-R1-associated death domain protein, and
Fas-associated death domain protein. The latter can then
recruit a cysteine protease, caspase-8, to the receptor com-
plex, where it is activated possibly by proteolytic cleavage
mediated by itself. Such autoactivation of caspase-8 is be-
lieved to initiate an amplifying caspase cascade leading to
the activation of so-called effector caspases, caspase-3 and
caspase-7, that cleave a limited set of cellular proteins re-
sulting in apoptotic morphology and death (Thornberry
and Lazebnik, 1998).
Several studies with caspase inhibitors and mice defi-
cient for various caspases have supported the involvement
of caspases in various forms of mammalian apoptosis, in-
cluding that induced by TNF and related death-inducing
ligands, TNF-related apoptosis-inducing ligand (TRAIL)
and CD95 ligand (Thornberry and Lazebnik, 1998; Ash-
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Abbreviations used in this paper:
 
 AFC, 7-amino-trifluoromethylcou-
 
marin; ALLN, 
 
N
 
-Acetyl-leu-Leu-Nle-CHO; anti-CD95, agonistic antibody
against CD95; Boc-D-fmk, Boc-Asp-CH
 
2
 
F; DEVD-CHO, acetyl-Asp-
Glu-Val-Asp-aldehyde; IETD-CHO, acetyl-Ile-Glu-Thr-Asp-aldehyde;
lactacystine, clasto-lactacystin-
 
 
 
-lactone; LDH, lactate dehydrogenase;
MEF, murine embryonic fibroblast; MTT, 3-(4,5-dimethylthiazole-2-yl)-
2,5-diphenyltetrazolium bromide; NF-
 
 
 
B, nuclear factor 
 
 
 
B; PS, phos-
phatidylserine; rhTNF, recombinant human TNF; rmTNF, recombinant
 
murine TNF; TLCK, 
 
N
 
-
 
 
 
-Tosyl-
 
L
 
-Lys-chloromethyl ketone; TNF, tumor
necrosis factor; TNF-R, TNF receptor; TPCK, tosyl-
 
L
 
-Phe-chloromethyl
ketone; TRAIL, TNF-related apoptosis-inducing ligand; zFA-fmk, z-Phe-
Ala-CH
 
2
 
F; zFK-mbmk, z-Phe-Lys-2,4,6-trimethylbenzoyloxymethylke-
tone; zVAD-fmk, z-Val-Ala-DL-Asp-CH
 
2
 
F; zVDVAD-fmk, z-Val-
Asp(OMe)-Val-Ala-Asp(OMe)-CH
 
2
 
F. 
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kenazi and Dixit, 1999; Wallach et al., 1999). However,
noncaspase proteases such as cathepsins D (Deiss et al.,
1996) and B (Guicciardi et al., 2000), calpains (Vanags et
al., 1996), and various serine proteases (Ruggiero et al.,
1987; Wright et al., 1994) have been reported as essential
downstream effectors of caspases, for instance, in TNF-
mediated apoptosis. It has only lately become evident that
apoptosis can also occur in the complete absence of cas-
pase activation (Lavoie et al., 1998; Mathiasen et al., 1999;
Nylandsted et al., 2000). In parallel, it was found that
death receptors, which were originally believed to induce
cell demise only via the direct activation of the caspase
cascade, may simultaneously activate mechanistically dif-
ferent death pathways, leading either to necrosis or apop-
tosis. The first demonstration of the existence of such
overlapping death pathways took advantage of the re-
quirement for ATP for the apoptotic process. The prede-
pletion of Jurkat or HeLa cells of ATP prevented caspase
activation, and the stimulation of CD95 in such ATP-
depleted cells resulted in necrosis (Eguchi et al., 1997;
Leist et al., 1997). A similar switch from TNF-induced
apoptosis to necrosis was then observed in L929 and U937
cells in the presence of a potent peptide caspase inhibitor
z-Val-Ala-DL-Asp-CH
 
2
 
F (zVAD-fmk) (Vercammen et
al., 1998; Khwaja and Tatton, 1999). Interestingly, in
NIH3T3 cells, the inhibition of caspase activation did not
change the mode of cell death, but enhanced apoptosis-
like process induced by TNF, TRAIL, or agonistic anti-
body against CD95 (anti-CD95; Luschen et al., 2000). The
mediators of this caspase-independent/receptor-induced
death have remained obscure.
This study was initiated by our surprising observation
that low but effective concentrations of pan-caspase inhib-
itors sensitized WEHI-S fibrosarcoma cells to TNF-induced
cytotoxicity. Characterization of this death process clearly
demonstrated that TNF-treated WEHI-S cells died in
an identical apoptosis-like manner both in the presence
and absence of caspase inhibitors. These findings prompted
us to search for alternative noncaspase mediators of
apoptosis and resulted in the identification of cathepsin B
as an essential mediator of TNF-induced tumor cell
apoptosis.
 
Materials and Methods
 
Cells and Treatments
 
WEHI-S, ME-180as (ME-ashsp2), and MCF-7S1 cells were propagated
as described (Jäättelä et al., 1998). Murine embryonic fibroblasts (MEFs)
from wild-type, cathepsin B–deficient (Deussing et al., 1998), or cathepsin
S–deficient (Shi et al., 1999) mice were used for experiments at passages
3–5. Primary murine hepatocytes were prepared as described (Leist et al.,
1994).
The recombinant human TNF (rhTNF) was provided by A. Cerami
(Kenneth Warren Laboratories, Tarrytown, NY), and Flag-TRAIL, by J.
Tschopp (University of Lausanne, Epalinges, Switzerland). Recombinant
mTNF was from R&D Systems, and anti-CD95 (Jo-2) from was from BD
PharMingen. Protease inhibitors used included z-Phe-Lys-2,4,6-trimeth-
ylbenzoyloxymethylketone (zFK-mbmk), zVAD-fmk from Bachem,
z-Val-Asp(OMe)-Val-Ala-Asp(OMe)-CH
 
2
 
F (zVDVAD-fmk), 
 
N
 
-Acetyl-
leu-Leu-Nle-CHO (ALLN), PD 150606, clasto-lactacystin-
 
 
 
-lactone (lac-
tacystine) from Calbiochem-Novabiochem, CA-074-Me, Boc-Asp-CH
 
2
 
F
(Boc-D-fmk) from Peptides International, z-Phe-Ala-CH
 
2
 
F (zFA-fmk)
from Enzyme System Products, pepstatin A, 
 
N
 
-a-Tosyl-
 
L
 
-Lys-chloro-
methyl ketone (TLCK), tosyl-
 
L
 
-Phe-chloromethyl ketone (TPCK) from
 
Roche Biochemicals, acetyl-Asp-Glu-Val-Asp-aldehyde (DEVD-CHO),
and acetyl-Ile-Glu-Thr-Asp-aldehyde (IETD-CHO) from Biomol.
 
Survival Assays and Detection of Apoptotic Markers
 
The 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
reduction and lactate dehydrogenase (LDH) release assays were used to
analyze the survival of the cells as described (Jäättelä et al., 1998; Latta et
al., 2000). The clonogenic survival of ME-180as cells was determined by
replating cells treated as indicated at serial dilutions on cloning plates
(Greiner) and counting viable colonies 7 d later.
Apoptotic nuclear changes were identified by staining of cells with a
mixture of 0.5 
 
 
 
g/ml H-33342 and 1 
 
 
 
M SYTOX (Molecular Probes) as
described (Leist et al., 1997).
The externalization of phosphatidylserine (PS) was visualized by stain-
ing with FITC-annexin V (Molecular Probes) of propidium iodide-nega-
tive cells. Confocal microscopy, equipped with a TCS-4D system including
UV laser (DMB-IRB; Leica), was performed as described (Leist et al.,
1997). The electron microscopy (Philips 201) was performed as described
(Nylandsted et al., 2000), except that cells were fixed in situ for 10 min in
50% Karnovsky solution before the scraping.
 
Time-Lapse Microscopy
 
Cells were grown in four-well dishes (Greiner) to 40% confluence. For ex-
periments, serum-free L15 medium (CO
 
2
 
-independent pH buffering) was
used, and the culture dishes were equipped with a needle thermosensor
and mounted on an electronically controlled heating block fixed on a mi-
croscope stage (35 
 
  
 
0.3
 
 
 
C). Images were recorded by a 40
 
 
 
 Varell con-
trast microscopy (Axiovert-25; ZEISS) at 10-s intervals for 750 min at a
resolution of 768 
 
 
 
 576 pixels. The images in Fig. 2 C correspond to 120 
 
 
 
120 pixels of the original video frame, and the processed video sequences
correspond to the pictures shown in the figure. The number of video
frames was reduced to a total of 600 for all sequences during the transfor-
mation into Quicktime format, and replay speed is 15 frames/s, with every
second corresponding to 6 min in real time.
 
Analysis of Protease Inhibitors
 
For the determination of apparent 
 
IC
 
50
 
 values for irreversible inhibitors
and 
 
IC
 
50 
 
values for reversible inhibitors, inhibitors were incubated at serial
dilutions with the cell lysate (4 
 
 
 
 10
 
5
 
 cells/ml) or 10 pg/ml of caspase-2,
caspase-3, or caspase-8 (R&D Systems) in lysis buffer (25 mM Hepes, 5
mM MgCl
 
2
 
, 1 mM EGTA, 0.5% Triton-X-100, 5 mM DTT, 1 mM pefa-
block, pH 7.5) or 1.5 U/ml rabbit skeletal muscle calpain (Sigma) in
calpain assay buffer (50 mM Tris, pH 7.5, 8 mM DTT) for 20 min at 25
 
 
 
C
before the measurement. The enzyme activities were estimated by adding
one volume of 20 
 
 
 
M zVDVAD-7-amino-trifluoromethylcoumarin
(AFC) (Calbiochem-Novabiochem) for caspase-2, Ac-DEVD-AFC (Bio-
mol) for caspase-3, zRR-7-amino-4-methylcoumarin (AMC) (Calbio-
chem-Novabiochem) or zFR-AFC (Enzyme System Products) for cathep-
sins B and L, and 100 
 
 
 
M succinyl-LLVY-AMC (Bachem) plus 2 mM
Ca
 
2
 
 
 
 for calpain measurements in appropriate reaction buffers; i.e., cas-
pase reaction buffer (100 mM Hepes, 20% glycerol, 0.5 mM EDTA, 0.1%
CHAPS, 5 mM DTT, 1 mM pefablock, pH 7.5), cathepsin reaction buffer
(50 mM sodium acetate, 4 mM EDTA, 8 mM DTT, 1 mM pefablock, pH
6.0), cathepsin L reaction buffer (4 M urea, 20 mM sodium acetate, 4 mM
EDTA, 8 mM DTT, 1 mM pefablock, pH 5.0), and calpain assay buffer.
The 
 
V
 
max
 
 of the liberation of AFC (excitation 400 nM, emission 489 nM)
or AMC (380 nM, 442 nM) was measured over 20 min at 30
 
 
 
C with a Spec-
tramax Gemini fluorometer (Molecular Devices). The specific cathepsin
B activity was calculated from the difference of the 
 
V
 
max
 
 values in the ab-
sence and presence of 0.1 
 
 
 
M zFK-mbmk. 
 
IC
 
50
 
 values were calculated by
a four-parameter fit procedure using Graph Pad-Prism software.
 
Measurement of Total Cellular Cysteine Protease Activities
 
Cells were treated as indicated and washed twice with PBS before the lysis
and analysis of intracellular protease activities was performed as de-
scribed above. The caspase-2 activity was measured in the presence of 50
nM DEVD-CHO.
 
Measurement of Cytosolic Cathepsin Activities
 
To measure cysteine cathepsin activity in the cytosol, experiments were
performed under serum-free conditions. After the removal of the me- 
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dium, extraction buffer (25 
 
 
 
g/ml digitonin, 250 mM sucrose, 20 mM
Hepes, 10 mM KCl, 1.5 mM MgCl
 
2
 
, 1 mM EDTA, 1 mM EGTA, 1 mM
pefablock, pH 7.5) was added, and cells were incubated for 5 min (ME-
180as) or 15 min (WEHI-S) on ice. The digitonin concentration and treat-
ment times were optimized to result in the total release of cytosolic LDH
activity without disruption of lysosomes. Cathepsin and LDH activities in
the resulting supernatant were determined as described above, and the cy-
tosolic cathepsin activity is expressed as the ratio of the cathepsin activity
and the LDH activity within one sample.
 
Transfections
 
Transient transfections were performed using lipofectamine reagents
(Life Technologies). The plasmids pBK-CystA (Jones et al., 1998) and
pEGFP-hCathB (Roberts et al., 1997) encoding for rat cystatin A and
GFP–cathepsin B, respectively, were provided by G. Gores (Mayo Clinic,
Rochester, MN). The antisense cathepsin B plasmids were created by
cloning PCR products complementary to bases 116–482 (pcDNA-as-
mCathB-1) or 642–843 (pcDNA-as-mCathB-2) of the murine cathespsin
B (EMBL/GenBank/DDBJ under accession no. NM_007798) and bases
175–551 (pcDNA-as-hCathB-1) or 561–911 (pcDNA-as-hCathB-2) of the
human sequence (EMBL/GenBank/DDBJ under accession no. M14221)
into the cloning site of the pcDNA3-neo (Invitrogen). Similar constructs
containing antisense cathepsin D were used as controls. The transfected
cells were visualized by co-transfection (1:10) of pEGFP-N1 (CLON-
TECH Laboratories, Inc.).
 
Analysis of Nuclear Factor 
 
 
 
B Activation
 
Transient transfections were performed by electroporation using 5 
 
 
 
g of
p3K-INF-LUC containing three copies of a consensus nuclear factor 
 
 
 
B
(NF-
 
 
 
B) binding sequence in front of human minimal interferon pro-
moter and 
 
Photinius pyralis
 
 luciferase cDNA and 3 
 
 
 
g of pEBS-
 
 
 
-Gal per
10
 
6
 
 cells (Jäättelä et al., 1995). 2 d after the transfection, cells were treated
as indicated, harvested, and analyzed for luciferase and 
 
 
 
-galactosidase
activities as described previously (Jäättelä et al., 1996).
 
Analysis of Receptor Binding, Internalization, 
and Degradation
 
Subconfluent cells growing on six-well plates (Nunc) were treated with
protease inhibitors as indicated for 1 h before a 90-min incubation with 1
nM 
 
125
 
I-labeled TNF (
 
 
 
30 
 
 
 
Ci/
 
 
 
g; NEN Life Science Products) on ice,
surface bound, and internalized. Degraded 
 
125
 
I-labeled TNF were ana-
lyzed as described previously (Tsujimoto et al., 1985).
 
Immunocytochemistry, Lysosomal Staining,
and Immunoblotting
 
Cells were fixed in methanol, treated with 1% H
 
2
 
O
 
2
 
, and stained with
cathepsin B antibody (1:200; Oncogene Research Products), biotinylated
anti–mouse-IgG (Dako), peroxidase-conjugated streptavidin–biotin com-
plex, and diaminobenzidine/H
 
2
 
O
 
2
 
 as substrate according to the manufac-
turer’s instructions (StreptABC, Vector Laboratories). Images were re-
corded with an Olympus digital camera mounted on an Olympus BX60
microscope.
The lysosomal–cytoplasmic pH gradient was visualized by a Leica TCS-
4D confocal microscope equipped with a 40
 
 
 
 long-distance lens in cells
incubated for 1 min with 10 nM LysoTracker red (Molecular Probes). The
specificity was demonstrated by complete inhibition of staining after pre-
treatment with 40 mM NH
 
4
 
Cl. The cytosol was counterstained by a 2-min
preincubation with calcein-AM (0.5 
 
 
 
M; Molecular Probes).
Immunodetection of proteins separated by SDS-PAGE and trans-
ferred to nitrocellulose was performed with enhanced chemiluminesence
Western blotting reagents (Amersham Pharmacia Biotech). Rabbit poly-
clonal antibodies to caspase-3 (BD PharMingen), murine caspase-7 (P.
Vandenabeele, University of Gent, Gent, Belgium), Bid (S. Korsmeyer,
Harvard Medical School, Boston, MA), or cPLA
 
2 
 
(Wissing et al., 1997)
and mouse monoclonal anti-Hsc70 (B. Margulis, Russian Academy of Sci-
ences, St. Petersburg, Russia) were used as primary antibodies. Peroxi-
dase-conjugated secondary antibodies were from Dako.
 
Online Supplementary Material
 
Four video sequences of dying WEHI-S cells demonstrate that TNF in-
duces morphologically indistinguishable apoptosis in the presence and ab-
sence of 1 
 
 
 
M zVAD-fmk, and that CA-074-Me inhibits all apoptotic
changes observed. Videos are available at http://www.jcb.org/cgi/content/
full/153/5/999/DC1.
 
Results
 
Caspase Inhibitors Sensitize WEHI-S Cells 
to Death Receptor–induced Apoptosis
 
TNF induces both caspase activation and apoptosis in
WEHI-S murine fibrosarcoma cells (Jäättelä et al., 1996;
Faraco et al., 1999). To further characterize this death
pathway, we evaluated the necessity of caspase activity for
apoptosis induction in this model system. First, we com-
pared the concentration dependence of zVAD-fmk for the
inhibition of effector caspase (DEVDase) activity and
apoptosis. Although 0.8 
 
 
 
M zVAD-fmk completely inhib-
ited TNF-induced DEVDase activity in WEHI-S cells,
concentrations of over 30 
 
 
 
M were required to confer pro-
tection against TNF-induced apoptosis (Fig. 1, A–C). As
the initiator caspase-8 is even more sensitive to inhibition
by zVAD-fmk than effector caspases (Table I) (Garcia-
Calvo et al., 1998), the classical death receptor–mediated
apoptosis pathway is likely to be completely blocked by 1
 
 
 
M zVAD-fmk. Since caspase-2 is less susceptible to the
inhibition by zVAD-fmk than other caspase family mem-
bers (Garcia-Calvo et al., 1998), the requirement of high
zVAD-fmk concentrations for the protection of WEHI-S
cells against TNF could be due to the involvement of this
isozyme in the death signaling. However, neither had the
potent caspase-2 inhibitor zVDVAD-fmk any effect on
TNF-induced death of WEHI-S cells (Fig. 1 D), nor was any
significant caspase-2–like activity detectable in WEHI-S
cells treated with TNF (not shown).
Low zVAD-fmk concentrations (0.2–3 
 
 
 
M) correlating
with the progressive inhibition of the DEVDase activity
not only failed to rescue WEHI-S cells from apoptosis, but
sensitized them up to 50-fold to recombinant murine TNF
(rmTNF) (Fig. 1 B). Caspase inhibition appeared to have
sensitized WEHI-S cells to TNF-R1–mediated apoptosis,
because 1 
 
 
 
M zVAD-fmk enhanced also apoptosis in-
duced by rhTNF, which binds selectively to the murine
TNF-R1 (Tartaglia et al., 1991). Also, another pan-caspase
inhibitor (Boc-D-fmk) sensitized WEHI-S cells to rhTNF
at low concentrations (0.3–3 
 
 
 
M) and conferred full pro-
tection only at concentrations 
 
 
 
30 
 
 
 
M (Fig. 1 C). The sen-
sitizing effect was, however, specific with respect to the
stimulus and the sensitizer: 1 
 
 
 
M zVAD-fmk or Boc-
D-fmk had no effect on death induced by puromycin, dox-
orubicin, staurosporine, H
 
2
 
O
 
2
 
,
 
 
 
or heat, whereas apoptosis
induced by TRAIL was greatly enhanced (Fig. 1 E). More-
over, micromolar concentrations of DEVD-fmk, zFA-
fmk, or VDVAD-fmk did not interfere with TNF signaling
by a potentially unspecific effect of the fmk group,
whereas a structurally different inhibitor of caspase-8
(IETD-CHO) sensitized WEHI-S cells to TNF (Fig. 1 D).
As judged by chromatin condensation, the mode of
TNF-triggered death was clearly apoptotic, independently
of whether caspases were inhibited or not (Fig. 2 A).
These observations were confirmed by electron micros-
copy (Fig. 2 B), and also the analysis of time-lapse video
microscopy sequences showed that low zVAD-fmk con- 
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centrations accelerated the onset of death but did not
change its morphological features (Fig. 2, C and D; supple-
mentary videos available at http://www.jcb.org/cgi/content/
full/153/5/999/DC1). Thus, caspase activation may only be
an epiphenomenom of apoptosis in this model. Accord-
ingly, TNF concentrations used in this study failed to in-
duce caspase-8 activity (IETDase) as well as processing of
caspase-7, caspase-8, and several known caspase sub-
strates in WEHI-S cells (Fig. 3; data not shown). A signifi-
cant percentage of pro-caspases or caspase substrate pro-
teins was cleaved only when over 100-fold higher
concentration of TNF was used (Fig. 3). Together with the
fact that the inhibition of DEVDase activity accelerated
the kinetics and extent of TNF-induced WEHI-S cell
apoptosis, it is likely that the death pathway triggered by
low TNF concentrations is caspase-independent also in the
absence of zVAD-fmk.
Since full sensitization by zVAD-fmk was observed
even when it was added 2 h after TNF, receptor availabil-
ity and the potential for activation of receptor-driven sig-
 
Table I. Specificity Profile of Protease Inhibitors Used to Define Cathepsin B–mediated Apoptosis
 
Apparent 
 
IC
 
50 
 
Supposed specificity Rec. casp3 Rec. casp2 Rec. casp8 DEVDase* casp3/7 zFRase (cathB) zFRase (cathL) Muscle calpain
 
 
 
M
 
zVAD-fmk pan-casp 0.15 0.3
 
  
 
0.1
 
  
 
0.1 8
 
 
 
100
 
 
 
100
Boc-D-fmk pan-casp 0.5 100 1 3 20
 
 
 
100
 
 
 
100
DEVD-CHO casp3
 
  
 
0.1 2.3
 
  
 
0.1
 
  
 
0.1 50 ND
 
 
 
100
IETD-CHO casp8 0.1 8
 
  
 
0.1 0.1 90 ND 95
CA-074-Me cathB
 
 
 
100
 
 
 
100
 
  
 
100
 
  
 
100 0.5 55
 
 
 
100
zFA-fmk cathB/L
 
 
 
100 60
 
  
 
100 100
 
  
 
0.1
 
  
 
0.1 ND
zFK-mbmk cathB 80 80 90 50
 
  
 
0.1 10 3
pepstatin cathD
 
 
 
100
 
 
 
100
 
  
 
100
 
 
 
100
 
 
 
100 ND
 
 
 
100
TPCK ser. prot.
 
 
 
100  100   100  100 50 ND  100
ALLN calpain  100  100   100  100    0.1   0.1 1.2
casp, caspase; cath, cathepsin; Rec., recombinant; ser. prot., serine protease. 
*Enzyme activities in WEHI-S cell lysates treated with 0.1 ng/ml rhTNF for 5 h.
Figure 1. Inhibition of caspase activation sensitizes WEHI-S cells
to death receptor–mediated apoptosis. (A) The DEVDase activity
in lysates of cells treated as indicated for 4 h was quantitated by
measurement of the cleavage of DEVD-AFC. The enzyme activ-
ity is expressed as arbitrary units. (B) Cells were incubated with
the indicated concentrations of zVAD-fmk for 1 h before a 10-h
treatment with rmTNF. The viability of the cells was measured by
LDH-release and MTT assays. (C) Cells were treated for 1 h with
indicated concentrations of pan-caspase inhibitors before an 11-h
treatment with or without rhTNF. The survival of the cells was
measured by the MTT assay. (D) WEHI-S cells were pretreated
with indicated protease inhibitors for 1 h before the addition of
100 pg/ml of rhTNF. The survival of the cells was analyzed 12 h
later by the MTT assay. (E) Cells were treated with caspase inhib-
itors for 1 h before a 22-h treatment with 4  g/ml of puromycin
(Puro) or doxorubicin (Doxo), 100 ng/ml of staurosporine
(Stauro), or 50  M H2O2, a 16-h treatment with 75 ng/ml of Flag-
TRAIL plus 2  g/ml of anti-Flag antibody (TRAIL), or a 45-min
treatment at 43.5 C followed by 18 h at 37 C (Heat). The survival
of the cells was measured by the MTT assay. *p-value   0.001,
**p-value   0.01; as compared with the control. All values repre-
sent means of triplicate determinations   SD.Foghsgaard et al. Cathepsin B in Death Receptor–induced Apoptosis 1003
naling in general appeared to have been unaffected (Fig. 4
A). In line with this, pretreatment of cells with 1  M
zVAD-fmk had no effect on the TNF-induced activation
of NF- B (Fig. 4 B) or on the binding, internalization, or
degradation of TNF (Fig. 5 C).
Cathepsin B Is a Mediator of Death Receptor–triggered 
Apoptosis of WEHI-S Cells
Next, we examined whether the protective activities of
high concentrations of pan-caspase inhibitors could be due
to the inhibition of proteases other than caspases. For in-
stance, zVAD-fmk has been shown to inhibit lysosomal
cysteine proteases (Schotte et al., 1999), which have re-
cently been reported to contribute to hepatocyte apoptosis
(Roberts et al., 1997; Guicciardi et al., 2000). Thus, we
studied the effect of a panel of protease inhibitors on
TNF-induced cell death. Compounds reported to inhibit
lysosomal cysteine proteases (ALLN and zFA-fmk) as
well as those more specific for cathepsin B (CA-074-Me
and zFK-mbmk) conferred significant protection against
TNF-induced apoptosis in WEHI-S cells, whereas inhibi-
tors of calpains (PD 150606), the proteasome (lactacystin),
serine proteases (TLCK and TPCK) or aspartic proteases
including cathepsin D (pepstatin A), had no significant ef-
fect when applied at serial dilutions up to maximal toler-
ated concentrations (Fig. 5 A). Thorough in vitro analysis
of the efficacy profiles of the protease inhibitors revealed
that the protective effect agreed best with the inhibition of
Figure 2. TNF-treated WEHI-S cells display apoptotic morphol-
ogy in the absence of caspase activity. (A) Chromatin of WEHI-S
cells was imaged by confocal microscopy. Cells treated with
rmTNF or TNF plus zVAD-fmk are shown at the initiation of
chromatin condensation. Cotreatment with 30  M CA-074-Me
inhibited chromatin condensation. For comparison, chromatin of
untreated control cells is shown. Chloroquine- and staurosporine-
exposed cells are shown as control for necrosis and apoptosis, re-
spectively. (B) WEHI-S cells were treated for 6 h as indicated,
fixed in situ, and prepared for transmission electron microscopy.
Condensed and fragmented chromatin lumps, nuclear fragmenta-
tion, and loss of cell surface microvilli were induced by TNF in
the presence or absence of zVAD-fmk. Bars, 2  m. (C) WEHI-S
cells were exposed to 5 pg/ml rmTNF or indicated combinations
of 0.2 pg/ml rmTNF, 1  M zVAD-fmk, and CA-074-Me (30  M)
and recorded by time-lapse microscopy (also see supplementary
videos available at http://www.jcb.org/cgi/content/full/153/5/999/
DC1). Note the continuous membrane movements in control
cells. Two different types of blebbing in TNF–treated cells are
marked as early (highly dynamic, multifocal, apoptotic blebbing)
and late (formation of a single large bleb on one side of the cell)
events. In necrotic death, only the latter occurs (data not shown).
Blebbing characteristics were not significantly modified by
zVAD-fmk, and quantitative analysis showed an average
blebbing time of 21   2 min (n   43) for TNF and 18   2 min
(n   37) for TNF plus zVAD-fmk. The very few cells that died in
the presence of CA-074-Me showed a distinct blebbing behavior
with average blebbing time of 50   9 min (white arrows). During
that time cells recovered from blebbing and looked normal (*)
for 13   5 min (n   20), before the final lethal bleb formed. (D)
WEHI-S cells were exposed to indicated combinations of rmTNF
(0.2 pg/ml), zVAD-fmk (1  M), and CA-074-Me (30  M) and re-
corded by time-lapse microscopy. For quantitative analysis of
bleb formation, every cell (40–50) in the field was included, and
the time between the addition of TNF and the start of the
blebbing was measured. Data for each experiment is presented as
cumulative frequency of cells that have initiated blebbing at a
given time point.The Journal of Cell Biology, Volume 153, 2001 1004
Cathepsin B Is an Essential Downstream Mediator 
of Caspase-initiated Tumor Cell Apoptosis
To test whether the requirement of cathepsin B–like en-
zymes was a particularity of WEHI-S cells, we tested the
effect of cathepsin B inhibition on ME-180as cervix carci-
noma cells. First, we demonstrated that these cells display
classical apoptotic morphology and die in a caspase-depen-
dent manner upon TNF treatment (Fig. 6, A and B). Inter-
estingly, CA-074-Me as well as the expression of two inde-
pendent antisense cDNAs complementary to the human
cathepsin B sequence potently inhibited also this caspase-
dependent cell death (Fig. 6, B and C). The functionality of
the two antisense constructs was demonstrated by their
ability to inhibit the expression of GFP–cathepsin B fusion
Figure 3. Absence of signif-
icant caspase-mediated in-
tracellular proteolysis in
WEHI-S cells exposed to low
but lethal concentration of
TNF. Equal amounts of pro-
tein from WEHI-S cells
treated for indicated times
with 0.1 or 50 ng/ml of
rhTNF were analyzed for
cleavage of caspase-7 or
caspase substrates cPLA2
and Bid by immunoblot anal-
ysis. The arrowhead indicates a caspase cleavage product of
cPLA2 (Wissing et al., 1997). Hsc70 serves as a loading control.
the cathepsin B–like activity (Table I). Therefore, we
chose CA-074-Me for the further studies. According to all
viability parameters, WEHI-S cells treated with 30  M
CA-074-Me were protected against TNF, even in the pres-
ence of sensitizing concentrations of zVAD-fmk or the
protein synthesis inhibitor cycloheximide (Figs. 2 and 5 B).
CA-074-Me also blocked TRAIL-induced apoptosis of
WEHI-S cells but did not affect the cytotoxicity induced
by puromycin, doxorubicin, staurosporine, H2O2, or heat
(Fig. 5 C). To further challenge the specific requirement of
cathepsin B in apoptosis induced by death receptors, we
followed two strategies independent of chemical inhibi-
tors. First, forced ectopic expression of cystatin A, an en-
dogenous inhibitor of cysteine cathepsins, attenuated
intracellular cathepsin activity by 59   1.5% and TNF-
induced apoptosis of WEHI-S cells almost completely
(Fig. 5 D). Second, expression of two independent and
nonoverlapping antisense cDNAs complementary to the
murine cathepsin B sequence in WEHI-S inhibited cathep-
sin activity in transfected cells by 53   1.9% or 44   3.8%,
correlating well with their ability to protect cells from TNF
(Fig. 5 D). The expression of a similar antisense construct
directed against murine cathepsin D had no effect on
WEHI-S cell sensitivity to TNF (not shown).
Cathepsin B Is Required for All TNF-induced 
Apoptosis-related Events in WEHI-S Cells
In individual WEHI-S cells appearing perfectly normal,
the blebbing was very abruptly initiated after variable
times (2–8 h) of TNF treatment (Fig. 2, C and D; sup-
plementary videos available at http://www.jcb.org/cgi/
content/full/153/5/999/DC1). The time from the initiation
of the blebbing to the lysis of the cell was, however, re-
markably constant ( 20 min). The release of cytochrome
c into the cytosol, PS exposure, and chromatin condensa-
tion were only detectable in blebbing cells (not shown).
All these events were completely absent in WEHI-S cells
rescued by CA-074-Me, suggesting that the entire death
process is cathepsin B dependent. Processing of TNF as
well as TNF-induced NF- B activation were, however, un-
affected by pretreatment with CA-074-Me, indicating that
TNF-R1 remained functional (Fig. 4, B and C). In line
with this, CA-074-Me conferred significant protection
against TNF even when added 2–4 h after TNF (Fig. 4 A).
Figure 4. Inhibition of caspase or cathepsin B activities does not
affect TNF-induced NF- B activation or binding, internalization,
or degradation of TNF. (A) WEHI-S cells were treated with 100
pg/ml rhTNF for 11 h and protease inhibitors as indicated. The
survival of the cells was measured by the MTT assay. (B) WEHI-S
cells transfected with p3K-INF-LUC and pEBS7- -Gal were left
untreated (control) or treated with 1 ng/ml of rhTNF for 4 h. 1  M
zVAD-fmk, 25  M CA-074-Me, or their combination was added
to the cells 1 h before the addition of TNF. NF- B activity is ex-
pressed as arbitrary units of luciferase activity relative to  -galac-
tosidase activity. (A and B) The values represent means of tripli-
cate determinations   SD, and the experiments were repeated
twice with similar results. (C) Subconfluent WEHI-S cells were
treated with indicated protease inhibitors for 1 h before a 90-min
incubation with 1 nM 125I-labeled TNF on ice. After careful wash-
ing, prewarmed complete medium containing the indicated pro-
tease inhibitors was added, and the cells were placed at 37 C (0
min). Receptor-bound, internalized, and degraded TNF at indi-
cated time points are shown. The values represent means of trip-
licate determinations. The experiment was repeated once with
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protein by 81   4.4% and 68   2.8%, respectively. The ex-
pression of GFP–actin was unaffected by antisense con-
structs in a similar assay. Importantly, the effect of cathep-
sin B inhibition was not merely a delay of the death
process, as the protected cells retained the ability of clonal
growth after the TNF challenge (Fig. 6 D). Also MCF-7
breast carcinoma cells dying in a caspase-dependent man-
ner were rescued from TNF-induced apoptosis by inhibi-
tors of cysteine but not aspartic cathepsins (Fig. 6 E). Inhi-
bition of TNF- or anti-CD95–induced apoptosis of primary
murine hepatocytes (Fig. 7 A) by CA-074-Me was rela-
tively minor compared with the effects observed in tumor
cells, even when very high ( 100  M) inhibitor concentra-
tions were used. zFA-fmk (50–150  M) failed to confer
any protection (data not shown). When primary fibroblasts
(early passages of MEFs) were exposed to TNF, the pro-
tective effect due to pretreatment with cathepsin inhibitors
or genetic deletion of cathepsin B was also clearly less pro-
nounced than that observed in tumor cells (Fig. 7 B).
TNF Induces a Translocation of Cathepsin 
B from Lysosomes to Cytosol
Next, we studied whether and how TNF-induced apoptosis
involves a modulation of the constitutive activity of ca-
thepsin B. Neither a significant increase in the protein levels
of pro-cathepsin B or mature cathepsin B nor in the total
cysteine cathepsin activity was observed. However, TNF
treatment resulted in cellular redistribution of the protein.
Cathepsin B disappeared from perinuclear granules (colo-
calizing with lysosomal markers) and distributed diffusely
throughout the cell (Fig. 8 A). To analyze the cytosolic
cathepsin B activities in intact cells, we developed a rapid
digitonin extraction method not requiring mechanical dis-
ruption of cells. Time course analysis revealed that the ap-
pearance of cathepsin B activity in the cytosol was a late
event that could not be temporally separated from the
Figure 5. Inhibition of cathepsin B activity or expression protects
WEHI-S cells from death receptor–induced apoptosis. (A)
WEHI-S cells were pretreated with indicated protease inhibitors
for 1 h before the addition of 100 pg/ml rhTNF. The survival of the
cells was analyzed 12 h later by the MTT assay. (B) WEHI-S cells
were treated for 11 h with indicated concentrations of CA-074-Me
and rhTNF in the presence or absence of 1  M zVAD-fmk or 10
 M cycloheximide (CHX). The cytotoxicity was measured by the
LDH release assay. (C) The survival of WEHI-S cells pretreated
with CA-074-Me for 1 h before the treatment with cytotoxic
agents, as indicated in the legend for Fig. 1 E (except for TRAIL
which was used at 150 ng/ml) was measured by the MTT assay.
(D) WEHI-S cells were transfected with indicated plasmids plus
pEGFP-N1 and treated 22 h later with rmTNF alone or with 1  M
zVAD-fmk or 20  M CA-074-Me. The survival of green cells was
determined 12 h later. The values represent means of triplicate de-
terminations (A–C) or means of 10 (D) randomly chosen fields of
 100 cells   SD. *p-value   0.01, as compared with control cells
(A and C) or to similarly treated vector-transfected cells (D).
Figure 6. Cathepsin B is a key mediator in TNF-induced
caspase-dependent apoptosis of tumor cells. (A) ME-180as cells
were treated as indicated for 24 h and analyzed by transmission
electron microscopy. Nuclear and chromatin condensation as
well as formation of apoptotic bodies was induced by TNF treat-
ment. Bar, 2  m. (B) The survival of ME-180as cells pretreated
with 200  M DEVD-CHO or IETD-CHO, 1  M zVAD-fmk, or
5  M CA-074-Me for 1 h before a 48-h treatment with 20 ng/ml
of rhTNF was analyzed by the MTT assay. (C) ME-180as cells
were transfected with indicated plasmids plus pEGFP-N1 and
treated 48 h later as indicated. The survival of the green cells was
analyzed after 48-h treatment. (D) After 3 d of treatment with in-
dicated combinations of 100 ng/ml rhTNF, 5  M zVAD-fmk, and
5  M CA-074-Me in serum-free medium, ME-180as cells were
replated on cloning plates in medium containing 6% FCS, and
the clonogenic potential was determined 7 d later by counting vi-
able colonies. (E) The survival of MCF-7 breast cancer cells pre-
treated with 1  M zVAD-fmk, 100  M zFA-fmk, or 12.5  M
ALLN for 1 h before a 32-h treatment with 10 ng/ml of rhTNF
was analyzed by the MTT assay. The values represent means of
triplicate determinations (B and E) or means of 10 randomly
chosen fields of  100 cells (C and D)   SD. *p-value   0.01, as
compared with control cells (B, D, and E) or similarly treated
vector-transfected cells (C).The Journal of Cell Biology, Volume 153, 2001 1006
LDH release in asynchronously dying cell populations
(Fig. 8 B). However, on the single-cell level, lysosomal
cathepsin release clearly preceded plasma membrane lysis
since cytosolic cathepsin activity was measured in cells
with intact plasma membranes. Moreover, our finding of
cathepsin B in the cytosol of cells protected by CA-074-
Me (Fig. 8 A) suggests that the release of the protease
from lysosomes occurs independently of the subsequent
lysis of the plasma membrane. Interestingly, lysosomes of
blebbing TNF-treated cells with a clear apoptotic mor-
phology retained the ability to accumulate acidic or-
ganelle-selective probes, indicating that the cytosolic–lyso-
somal pH gradient was not dissipated, and lysosomes
were, at least in part, intact (Fig. 8 C).
Cathepsin B Acts Downstream of Caspases 
in ME-180as Cells
The inhibition of ME-180as cell apoptosis by 1  M zVAD-
fmk was accompanied by the inhibition of the appearance
of cathepsin B protein and activity in the cytosol (Fig. 8, A
and B). Conversely, the inhibition of cathepsin B activity
had no effect on TNF-induced caspase activation as ana-
lyzed by either DEVDase enzyme assay or immunoblot-
ting using antibodies against caspase-3, -7, and -8 or
caspase substrates (cPLA2 and PARP) (Fig. 9, A and B;
data not shown). The initial rounding, NF- B activation,
and cathepsin B translocation were also unaffected by pro-
tective concentrations of CA-074-Me, whereas PS expo-
sure, formation of apoptotic bodies, and chromatin con-
densation were completely inhibited even in the rounded
cells (Figs. 8 and 9 C; data not shown). Thus, in TNF-
treated ME-180as cells, caspase activation appears to be a
reversible event leading to the cathepsin B translocation,
whereas cathepsin B activity appears indispensable for the
Figure 7. Cathepsin B plays a minor role in death receptor–
induced apoptosis of primary cells. (A) The survival of hepato-
cytes pretreated with the indicated concentrations of CA-074-Me
for 1 h before the addition of 200 nM actinomycin D plus 28 ng/ml
of rmTNF or 100 ng/ml of anti-CD95 antibody (Jo-2) was analyzed
after 22-h treatment by the LDH release assay. (B) MEF (passage
4) originating from wild-type, cathepsin B–, or cathepsin S–defi-
cient mice were left untreated or treated with 50  M CA-074-Me
or 100  M zFA-fmk for 1 h before an 18-h treatment with 100 ng/
ml of rhTNF plus 10  M cycloheximide. The survival was analyzed
by the MTT assay. The values represent means of triplicate deter-
minations   SD. *p-value   0.01, as compared with control cells.
Figure 8. TNF induces the appearance of active cysteine cathep-
sins in the cytosol. (A) ME-180as cells were left untreated (con-
trol) or treated with 20 ng/ml rhTNF, TNF plus 5  M CA-074-Me,
or TNF plus 1  M zVAD-fmk and stained with anti–cathepsin B
after 16-h treatment. (B) WEHI-S or ME-180as cells were
treated as indicated and analyzed for cytosolic cysteine cathepsin
activity within intact cells and for released LDH activity. The val-
ues represent means of a triplicate determination   SD. (C) ME-
180as cells were left untreated (control) or treated with 20 ng/ml
rhTNF for 30 h and stained with LysoTracker and calcein-AM.Foghsgaard et al. Cathepsin B in Death Receptor–induced Apoptosis 1007
final phases of the execution as well as the display of pha-
gocytosis markers.
Discussion
Since the demonstration that the developmentally pro-
grammed death of male linker cells in Caenorhabditis ele-
gans does not require the ced-3 gene product (Ellis and
Horvitz, 1986), there has been several further reports pro-
viding evidence for caspase-independent death programs
in vitro (Lavoie et al., 1998; Mathiasen et al., 1999; Ny-
landsted et al., 2000) and in vivo (Chautan et al., 1999;
Doerfler et al., 2000). Some of these death routines be-
come only evident when the caspase-dependent pathway
is inhibited, e.g., by pan-caspase inhibitors (Vercammen et
al., 1998; Khwaja and Tatton, 1999; Luschen et al., 2000),
mutations in caspases (Kawahara et al., 1998), or ATP de-
pletion (Eguchi et al., 1997; Leist et al., 1997). However, in
other models, cell death proceeds in the absence of any
sign of caspase activation (Lavoie et al., 1998; Mathiasen
et al., 1999; Nylandsted et al., 2000). Also, in such cases,
death retains the character of a program in the sense that
selective biochemical inhibitors can block death without
interfering with the initial triggering event. In this report,
we identified and characterized death receptor–mediated
tumor cell death that occurs independently of effector
caspase activation. This conclusion is based on three lines
of argumentation: (i) caspase substrates do not appear to
be cleaved, even though some DEVDase activity is trig-
gered in the cells; (ii) cell death proceeds equally well (or
rather faster) when caspase inhibitors are added; and (iii)
cell death has an apoptosis-like morphology that is not
changed by addition of caspase inhibitors.
It is still a matter of dispute whether the morphological
appearance of cell death reflects a single defined mecha-
nism. Although there is evidence that also caspase-inde-
pendent death can lead to some of the typically apoptotic
changes such as chromatin condensation, PS exposure,
and early phagocytic removal (Lavoie et al., 1998; Hirt et
al., 2000; Nylandsted et al., 2000), the classical apoptotic
morphology has been most closely linked to caspase acti-
vation. We examined the mode of death in the WEHI-S
model established here with special attention on the effect
of caspase inhibitors. Electron microscopy, light micro-
scopic video imaging, as well as fluorescent microscopy fo-
cussing on various apoptosis-related end points suggested
an apoptosis-like death process that was not affected by
the inhibition of the cellular DEVDase activity. This set of
data supports our suggestion that death of WEHI-S cells
induced by low TNF concentrations proceeds indepen-
dently of known caspases, and the DEVDase activity that
can be detected in these cells is an epiphenomenom, either
not linked to cell death at all or possibly involved in its
counter regulation (Luschen et al., 2000).
Although strong evidence is accumulating for pro-
grammed cell death occurring independent of caspases
(Wyllie and Golstein, 2001), the molecular identity of the
mediators remains to be elucidated in most cases. The
knowledge is particularly sparse for the well-characterized
model of death receptor–mediated alternative cellular de-
mise. There is vast evidence suggesting that many non-
caspase proteases like calpains (Vanags et al., 1996), the
proteasome (Grimm and Osborne, 1999), cathepsins
(Deiss et al., 1996; Roberts et al., 1999), and serine pro-
teases (Wright et al., 1997) can act in concert with caspases
in standard apoptotic processes. For instance, cathepsin B
can be involved in the upstream death signals of TNF in
hepatocytes by linking the death receptor to the mitochon-
drial enhancement loop of caspase activation (Guicciardi
et al., 2000). One molecular mechanism by which cathep-
sins might affect mitochondria has been identified recently
to be a selective proteolysis of Bid (Stoka et al., 2001). Our
study now gives complementary evidence that cathepsin B
Figure 9. TNF induces cathepsin B–independent activation of
caspases and cathepsin B–dependent translocation of PS in ME-
180as cells. (A and B) Equal amount of protein from cells treated
for indicated times with 20 ng/ml of rhTNF in the presence or ab-
sence of 1  M zVAD-fmk (zVAD) or 5  M CA-074-Me (CA) was
analyzed for caspase-3–like activity by DEVDase assay (DEVD-
ase activity is expressed as arbitrary units and values represent
means of triplicate determinations   SD) or immunoblot analysis
of caspase-3 or its substrate cPLA2. The arrowhead indicates a
cleavage product of cPLA2. Hsc70 serves as a loading control. (C)
ME-180as cells treated as indicated for 30 h were analyzed for PS
translocation by staining with FITC–annexin V. Note that in the
presence of CA-074-Me, TNF induces cellular shrinkage and
rounding in the absence of PS translocation.The Journal of Cell Biology, Volume 153, 2001 1008
can also be a downstream mediator of caspases in trigger-
ing TNF-signaled death in many human tumor cell lines.
Putting together these pieces of evidence, it appears possi-
ble that cathepsin B might, in certain situations, be suffi-
cient for all stages of apoptosis without requiring caspases.
This appears indeed to be the case in the TNF-induced
death of WEHI-S cells.
It is possible that different proteases may take a similar
role as cathepsin B in other circumstances. For example
there is good evidence for a dominant role of cathepsin D
in other systems (Deiss et al., 1996; Roberg and Ollinger,
1998). This might be due to the ratios of different pro-
teases and their inhibitors/activators in different cell types.
To get further evidence on the exact molecular identity of
the relevant protease in the model of WEHI-S cells ex-
posed to low concentrations of TNF, we first performed an
extensive screen of possible proteases using careful titra-
tions with a large panel of chemical protease inhibitors.
This seemed to exclude cathepsin D and pointed instead
to a cathepsin B–like protease. Further evidence was then
obtained by overexpression of cystatin A, which blocks
cysteine cathepsins like cathepsin B, but not calpains or
cathepsin D (Sloane et al., 1990). Cathepsin D was finally
excluded on the basis of antisense experiments, although
these experiments provided final definite evidence for
cathepsin B as the key protease involved in the WEHI-S
cell death model.
How is it possible that a specific cell death program can
be triggered by the rather unspecific digestive power of a
lysosomal protease? It appears as if a specific transloca-
tion process could be a key to the understanding of this
phenomenon. For instance the selective translocation of
cathepsin B from lysosomes to cytosol and nucleus is well
documented for bile salt–induced and TNF-triggered he-
patic apoptosis (Roberts et al., 1999; Guicciardi et al.,
2000). Similarly, there is clear evidence of early cathepsin
D translocation from secondary lysosomes to the cytosol
under conditions of oxidative stress–induced apoptosis
(Roberg and Ollinger, 1998). A second possibility is a
quantitative relationship between the amount of lysoso-
mal rupture and the mode of cell death. According to this
model, low stress intensities would trigger a limited release
of lysosomal enzymes to the cytoplasm followed by apop-
totic death, whereas high intensity stresses would lead to a
generalized lysosomal rupture and rapid cellular necrosis
(Brunk et al., 1997). A causal association between a lim-
ited lysosomal rupture and apoptosis has been supported
by experiments showing cytoprotection by membrane sta-
bilizing agents (Roberg and Ollinger, 1998) as well as trig-
gering of cell death by selective lysosomal disrupters (Li et
al., 2000). Our experiments showing clonal survival of cells
protected by the cathepsin inhibitor CA-074-Me, although
cathepsin B was released to the cytosol, suggest that trans-
location of lysosomal contents to the cytosol need not nec-
essarily be fatal for a cell. However, the mechanisms and
extent of cathepsin release awaits further elucidation.
The reasons why a single death receptor can trigger cel-
lular demise by several mechanisms remain a subject of
speculation at the current stage of knowledge. The cas-
pase-independent mechanisms could represent a backup
program especially important in pathological situations.
Tumor cells have frequently impaired standard apoptosis
routines due to, for example, mutations (Lowe and Lin,
2000), gene silencing (Soengas et al., 2001), or overexpres-
sion of survival proteins (Jäättelä, 1999). On the other
hand, lysosomal proteolytic efficacy has to be increased in
many transformed cells due to the higher protein turnover,
and also for enhanced invasiveness (Mai et al., 2000). This
would agree with our findings that the death receptor–trig-
gered cathepsin B–dependent death pathway appears to
take a more dominant role in tumor cells than in primary
cells. This selectivity could prove useful in cancer therapy
and it may be due to the fact that tumor cells have fre-
quently increased the expression of cysteine cathepsins
(Kos and Lah, 1998). Conversely, tumors that manage to
suppress the alternative death programs might have a se-
lective growth advantage. For instance, cathepsin-inacti-
vating cystatins may reduce the apoptosis susceptibility of
tumor cells. This latter antiapoptotic effect may contribute
to the recently reported aggressive phenotype of cystatin
A expressing tumors (Kuopio et al., 1998).
In conclusion, our data define two potent cathepsin
B–dependent apoptosis pathways in tumor cells that can
be triggered by TNF: one in WEHI-S cells, where cathep-
sin B functions as the dominant execution protease even in
the presence of pan-caspase inhibitors, and the other in
ME-180as cells with cathepsin B, as a downstream effector
of receptor-activated caspases. Our results further imply
that cathepsin B–like proteases and their endogenous in-
hibitors may have a dual role in tumor progression: the
proteases reducing malignancy by their pro-apoptotic fea-
tures but enhancing it by promoting invasion, and the op-
posite applying to the inhibitors.
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